The RNA landscape is expanding rapidly.
But understanding where the biggest opportunities lie is becoming increasingly complex.
As RNA therapeutics expand into new modalities, targets, disease areas and delivery technologies, understanding where innovation is accelerating requires a complete view of the RNA ecosystem.
The RNA H1 2026 Landscape Review provides a comprehensive analysis of the developments shaping the market. Drawing on Beacon RNA data, the series examines clinical progress, commercial activity, regulatory momentum and future milestones, helping teams better understand the forces driving change across the RNA landscape.
From emerging clinical trends and partnership activity to regulatory developments and upcoming catalysts, the review highlights the opportunities, risks and market shifts expected to influence RNA therapeutics throughout H2 2026 and beyond.
Part 1 of the series focuses on the RNA drug landscape, providing an essential foundation for the wider review and a data-driven snapshot of the competitive dynamics shaping the market today.
Report Contents
The Drug Landscape
502 new RNA assets added in H1 2026. Discover why circRNA is the fastest-growing modality, which targets are attracting investment, and how delivery innovations are reshaping the competitive landscape.
The Trial Landscape
269 trials initiated in H1 2026. Track the therapeutic classes, disease areas and sponsors driving the next wave of RNA clinical development.
The Commercial Landscape
5,225 deals and growing. Explore the partnerships, financings and acquisitions shaping investment across RNA therapeutics.
The Future of RNA Therapeutics
42 upcoming milestones already disclosed for H2 2026. See where the next catalysts are expected to emerge.
Regulatory Announcements
331 regulatory updates in six months. Monitor approvals, submissions and designations advancing RNA therapies toward commercialisation.
Previous RNA Landscape Reviews
RNA 2025 Landscape Review
An analysis of the RNA landscape in 2025
H1 2025 Landscape Review
Explore the defining RNA breakthroughs of H1 2025 and understand what’s shaping the RNA landscape next.
RNA 2024 Landscape Review
Uncover the key 2024 RNA breakthroughs and stay ahead in the rapidly evolving RNA landscape.
You May Also Be Interested In…
Learn More About RNA
- The Most Comprehensive Way to Search the RNA Drug Development Landscape: Unique search ontologies based on RNA drug and trial characteristics
- Market Leading Approach to RNA Preclinical & Clinical Data Curation: Manual curation of key RNA research and development data points by RNA research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search RNA company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
